XML 76 R34.htm IDEA: XBRL DOCUMENT
v3.20.1

Revenues (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2020 | Mar. 31, 2019
Disaggregation of Revenue [Line Items] |  |
Revenues | $ 5,548 | $ 5,281
U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 4,006 | 3,818
Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 975 | 938
Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 567 | 525
Atripla |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 95 | 171
Atripla | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 81 | 133
Atripla | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 7 | 16
Atripla | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 7 | 22
Biktarvy |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 1,693 | 793
Biktarvy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 1,412 | 739
Biktarvy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 181 | 48
Biktarvy | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 100 | 6
Complera/Eviplera |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 76 | 115
Complera/Eviplera | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 24 | 44
Complera/Eviplera | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 47 | 62
Complera/Eviplera | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 5 | 9
Descovy |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 458 | 342
Descovy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 363 | 233
Descovy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 61 | 68
Descovy | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 34 | 41
Genvoya |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 824 | 1,015
Genvoya | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 612 | 728
Genvoya | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 151 | 193
Genvoya | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 61 | 94
Odefsey |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 409 | 397
Odefsey | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 269 | 282
Odefsey | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 127 | 106
Odefsey | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 13 | 9
Stribild |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 53 | 96
Stribild | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 34 | 67
Stribild | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 17 | 18
Stribild | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 2 | 11
Truvada |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 406 | 606
Truvada | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 383 | 551
Truvada | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 8 | 33
Truvada | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 15 | 22
Other HIV |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 8 | 17
Other HIV | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 3 | 11
Other HIV | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 2 | 1
Other HIV | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 3 | 5
Revenue share - Symtuza |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 112 | 66
Revenue share - Symtuza | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 72 | 42
Revenue share - Symtuza | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 38 | 24
Revenue share - Symtuza | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 2 | 0
AmBisome |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 119 | 93
AmBisome | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 18 | 8
AmBisome | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 59 | 57
AmBisome | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 42 | 28
Ledipasvir/Sofosbuvir |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 112 | 225
Ledipasvir/Sofosbuvir | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 53 | 117
Ledipasvir/Sofosbuvir | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 11 | 27
Ledipasvir/Sofosbuvir | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 48 | 81
Letairis |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 83 | 197
Letairis | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 83 | 197
Letairis | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
Letairis | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
Ranexa |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 8 | 155
Ranexa | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 8 | 155
Ranexa | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
Ranexa | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
Sofosbuvir/Velpatasvir |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 564 | 491
Sofosbuvir/Velpatasvir | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 311 | 230
Sofosbuvir/Velpatasvir | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 122 | 154
Sofosbuvir/Velpatasvir | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 131 | 107
Vemlidy |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 136 | 101
Vemlidy | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 73 | 65
Vemlidy | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 7 | 4
Vemlidy | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 56 | 32
Viread |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 40 | 72
Viread | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 4 | 12
Viread | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 11 | 14
Viread | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 25 | 46
Vosevi |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 48 | 63
Vosevi | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 33 | 45
Vosevi | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 11 | 16
Vosevi | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 4 | 2
Yescarta |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 140 | 96
Yescarta | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 103 | 90
Yescarta | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 37 | 6
Yescarta | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 0
Zydelig |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 20 | 27
Zydelig | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 8 | 11
Zydelig | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 12 | 15
Zydelig | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 0 | 1
Other(3) |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 63 | 62
Other(3) | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 42 | 36
Other(3) | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 18 | 20
Other(3) | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 3 | 6
Product sales |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 5,467 | 5,200
Revenues | 5,467 | 5,200
Product sales | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 3,989 | 3,796
Product sales | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 927 | 882
Product sales | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 551 | 522
Royalty, contract and other revenues |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 81 | 81
Royalty, contract and other revenues | U.S. |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 17 | 22
Royalty, contract and other revenues | Europe |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | 48 | 56
Royalty, contract and other revenues | Other International |  |
Disaggregation of Revenue [Line Items] |  |
Revenues | $ 16 | $ 3

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_HCVProductsVoseviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |